Diabetes Drug Market- Size, Outlook, Trends and Forecast (2024 – 2032)

Diabetes is often referred by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond properly to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).

Diabetes Drugs Market Share:

Oral Diabetic Medication Drugs segment is expected to hold the largest share in the Global Diabetes Drugs Market in the forecast period 2018-2014.

Diabetes Drugs Market Size:

The diabetes drugs market, valued as a USD 30.98 billion market in 2018, is expected to grow at an exponential rate and become a USD 44.55 billion market by 2024, at a CAGR of about 7.7%.

Among North America, South America, Europe, Middle East & Africa, Asia-Pacific, North American Diabetes Drugs market holds the major share in the world market scenario. The market is valued at $22 billion in 2018 and is expected to reach $36.9 billion by the end of 2024 with a CAGR of 8.7%.

Diabetes Drugs Market Growth:

Rise in the number of diabetics, Complexities in alternative diabetic therapies, Strong encouragement from the governments are the major factors that are driving the growth of the market.

Diabetes Drugs Market Industry Analysis:

The market is segmented on the basis of diabetic drugs, devices, and geography. The diabetic drugs market is again segmented into categories, which are insulin derivatives and oral diabetic medication drugs. On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the World.

Diabetes Drugs Market Outlook:

The Diabetes market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose linked transporter 2 (SGLT-2) inhibitors.

Diabetes Drugs Market Trends:

Abbott had announced that the FreeStyle Libre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.  GSK submitted a supplemental Biologics License Application (sBLA) for mepolizumab, an interleukin-5 (IL-5) antagonist.

Diabetes Drugs Market Research report includes:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
• Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
• Expertise investment opportunities by an analyst to the individual and organization to have a better foothold in the market.
• Identify the latest developments, market shares and strategies that are employed by the major market players, such as
• Abbott Laboratories
• AstraZeneca PLC
• Bayer Healthcare AG
• Dexcom Inc.
• GlaxoSmithKline PLC